Skip to content

Bringing Possibilities to LIFE

End-to-end generic drug services — from API & dossier sourcing to market access across Asia.

Trusted byDr. Reddy'sCiplaAurobindoBoehringer Ingelheim+15 more
25+
38+
120+
80+
20+
The Group

The end-to-end partner for generic drug manufacturers in Asia.

Chemill is an end-to-end generic drug services group, headquartered in Hong Kong. We source APIs and dossiers, develop finished dosage forms, and open market access across Asia, so manufacturers can enter new markets faster, cut costs, and reach more patients.

Empowering clients. Driving market success. Fostering sustainable growth.

Making medicines accessible, safe, effective and affordable for everyone.

A pharmaceutical scientist dispensing samples into vials in a modern quality-control laboratory
The Opportunity

The rise of generic drugs in Asia.

Increasing patent expirations, ageing populations and the need for affordable medicines are fuelling one of the world's fastest-growing pharmaceutical regions.

USD 166.4B
Asia-Pacific generic drugs market (2020)
9.1% CAGR 2021–2028
USD 17.2B
Japan generics market by 2032
6.2% CAGR
USD 24.6B
India generic exports by 2030
from USD 16.1B in 2020
Asia-Pacific generic drugs marketUSD billion
Market size202020282020: USD 166.4B → 2028: USD 334B

The 2020 market size and the 9.1% CAGR quoted for 2021–2028 are as published in the sources below. The years between are that rate compounded — a projection, not separately reported figures — and are drawn dashed for that reason.

Asia-Pacific generic drugs market, USD billion — 2020 published, 2021–2028 modelled at 9.1% CAGR.
YearMarket size (USD billion)
2020166.4
2021181.5
2022198.1
2023216.1
2024235.8
2025257.2
2026280.6
2027306.1
2028334
Value Chain

One partner, the whole journey — from molecule to market.

We cover the entire supply chain so manufacturers can commercialize with confidence across Asia.

01

API Sourcing

Global network of pre-qualified, high-quality API manufacturers for reliable, cost-effective supply.

  • Commercial & precision sourcing
  • New-product APIs
  • Alternate vendor development
02

Dossier & FDF Development

Ready-made, validated dossiers and finished dosage forms for seamless market entry.

  • FDF dossiers, licensing & supply
  • Technology transfer
  • CDMO / CMO manufacturing
03

Market Access

Registration, enlistment and tendering that open public and private channels across the region.

  • Drug registration & enlistment
  • National / local tendering
  • Hospital supply
04

Distribution & Fulfilment

Last-mile distribution, inventory planning and SCM across traditional and digital channels.

  • Inventory planning & SCM
  • Multi-channel distribution
  • E-commerce reach
Divisions

Five capabilities. One integrated group.

Engage one unit or the whole chain — every Chemill capability is built to be done-for-you.

chemillAPI — Chemill division

API sourcing solutions

Immediate cost savings and enhanced competitive capabilities through comprehensive done-for-you sourcing.

  • Commercial API Sourcing
  • APIs for New Product Development
  • API Manufacturing (CMO / CDMO)
  • Precision API Sourcing
  • Alternate Vendor Development
chemillAPI+ — Chemill division

Value-added generics

Curated, ready-made, validated project dossiers for seamless market entry and immediate impact.

  • Commercial FDF Sourcing
  • FDF Dossiers Licensing & Supply
  • Technology Transfer
  • Project Management
  • FDF Manufacturing (CDMO / CMO)
chemillpharma — Chemill division

Market access solutions

Immediate access to new markets, leveraging our industry experience and expansive Asian network.

  • Market Research
  • Drug Registration & Enlistment
  • National / Local Tendering
  • Hospital Supply & Distribution
  • Ethical Sales & Marketing
  • Inventory Planning, SCM & Fulfilment
ValueLIFE — Chemill division

Consumer healthcare

Innovative consumer health and OTC products brought to retail and e-commerce across the region.

  • Innovative OTC & devices
  • Branding & Localisation
  • Key-chain & pharmacy enlistment
  • Sales, Marketing & E-commerce
  • Cross-border distribution
chemillBIOpharma — Chemill division

Innovative arm — biosimilars

Biosimilars, 505(b)(2) and innovative biotech drugs, accelerated into Hong Kong and across Asia.

  • Biosimilar registration
  • 505(b)(2) products
  • NCE / innovative biotech drugs
  • Pre-NDA & dossier strategy
  • Medical affairs & KOL liaison
  • Hospital Authority tendering
What We Stand For

Built on people, proven by commitments.

OwnershipResponsibilityIntegrityUrgency
Chemill colleagues reviewing product documentation together in the Hong Kong office

Improving Efficiency & Cost Reduction

Optimizing supply sources and operations to lift partner productivity and competitiveness.

Consistently Generate Value

Creating value for every stakeholder — clients, partners, employees and shareholders.

Highest Quality & Safety

Strict adherence to the highest quality and safety requirements at every step.

Make Choices Available

Giving manufacturers a wide range of suitable choices to excel in their markets.

Actively Create Opportunities

A dynamic environment where principals and partners thrive together.

Timely & Equitable Access

Ensuring safe, effective, affordable medicines reach the patients who need them.

Reach

A network built across Asia, trusted around the world.

Greater China
Hong KongHubP.R. ChinaTaiwan
North Asia
JapanSouth Korea
South & Southeast Asia
IndiaThailandVietnamPhilippinesMalaysiaIndonesiaSingapore

Serviced end-to-end from our Hong Kong hub — public and private hospitals, ethical and retail channels, and cross-border e-commerce across the region.

Channels we cover

Generic Drugs

  • Public Sector Hospitals
  • Private Sector Hospitals
  • Ethical Channels
chemillpharma

Offline Coverage

  • Key Chain Stores
  • Speciality Retail
  • Local Pharmacies
  • Elderly Homes
ValueLIFE

Consumer Health

  • Online Platforms
  • Cross-Border E-commerce
  • Hong Kong E-commerce
ValueLIFE
Trusted By

Trusted by top generic drug companies.

Partner names and marks shown for identification only — subject to partner display permissions.

Since 1999

A quarter-century of building access.

1999

Chemillennium International incorporated — pioneering API trade between India & China.

2002

Chemill Inc. USA — distributing nutraceuticals across North America.

2007

Acquired a GSP-licensed drug distribution company in China.

2010

First generic FDF product approval in Hong Kong.

2012

Chemill Pharma launched — first-to-market generics in Hong Kong.

2016

Chemillennium evolves into a dedicated API sourcing company.

2017

Chemill Pharma Ltd. established as an independent entity.

2021

Chemill ValueLIFE — consumer healthcare division — launched.

2022

Group rebrands to CHEMILL: full-spectrum generic drug services.

2024

A quarter-century in Asia — 200+ clients across 38+ countries, 120+ API clients.

2025

Chemill BIOpharma launched — biosimilars, 505(b)(2) and innovative biotech drugs, accelerated into Hong Kong and across Asia.

At Chemill, we stand committed to transforming possibilities into realities. Our unwavering dedication to excellence, precision, and accessibility fuels our mission to provide high-quality, affordable healthcare solutions. As we evolve, we promise to continue shaping a healthier, more connected world for all.

Unlock Value. Increase Impact. Expand your Reach.

Whether you need pre-developed dossiers, regulatory guidance, or reliable API & FDF supply — our specialists are ready.

We reply within one business day — or write to office@chemill.com

Prefer to talk?+852 2191 9580